Healthcare Services

Next Generation Immunotherapies Market Report 2026: Strategic Insights and Revenue Outlook

April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the next generation immunotherapies market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Next Generation Immunotherapies Market from 2026 to 2030?

The market size for next generation immunotherapies has expanded quickly in recent years. Its value is expected to increase from $150.12 billion in 2025 to $168.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.1%. This historical expansion can be linked to factors like the increasing global incidence of cancer, the initial positive outcomes from immune checkpoint inhibitors, enhanced investments in oncology research and development, regulatory endorsements for monoclonal antibodies, and a heightened understanding of immuno-oncology treatments.

The next generation immunotherapies market size is anticipated to undergo rapid expansion over the next few years. It is projected to climb to $262.82 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.8%. The projected increase in this period is driven by advancements in next-generation antibody engineering, the expansion of applications beyond oncology, a rise in the approval of ADC-based therapies, the growing use of biomarker-driven treatment selection, and an increasing need for durable and long-lasting treatments. Prominent trends for the forecast period involve the broadening of combination immunotherapy regimens, the development of personalized cancer vaccines, the increasing adoption of bispecific antibodies, a stronger emphasis on reducing immune-related adverse events, and accelerated clinical trial activities for solid tumors.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21231&type=smp

What Drivers Are Affecting Demand In The Next Generation Immunotherapies Market?

The expanding occurrence of cancer is anticipated to fuel the expansion of the next-generation immunotherapies market moving ahead. This condition encompasses a range of illnesses defined by the unchecked proliferation and dissemination of atypical cells within the body. Its widespread nature stems from elements like an aging demographic, shifts in lifestyle, environmental influences, and more effective diagnostic techniques. These cutting-edge immunotherapies offer sophisticated, targeted therapies designed to boost the body’s defensive reaction against cancer, delivering superior efficacy, lasting results, and tailored approaches. As an illustration, projections released by Cancer Research UK, a UK-based cancer charity, indicate that by July 2024, cancer incidence rates across the United Kingdom are foreseen to rise for a majority of types between the periods 2023-2025 and 2038-2040, showing increases from less than 1% for breast cancer up to 50% for eye cancer. Conversely, a limited number of cancer types are predicted to decrease, with declines varying from 2% for lung cancer to 27% for mesothelioma. Consequently, the rising incidence of cancer is propelling the growth of the next-generation immunotherapies market.

Which Segment Groups Are Influencing The Next Generation Immunotherapies Market?

The next generation immunotherapies market covered in this report is segmented –

1) By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors

2) By Route Of Administration: Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacies, Clinical Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Anti-PD-1 Antibodies, Anti-PD-L1 Antibodies, Anti-CTLA-4 Antibodies, Anti-CD20 Antibodies

2) By Antibody-Drug Conjugates (ADCs): HER2-Targeted ADCs, CD30-Targeted ADCs, CD19-Targeted ADCs

3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy, ACE Inhibitors For Other Indications

4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors

What Long-Term Trends Are Expected To Shape The Future Of The Next Generation Immunotherapies Market?

Leading companies active in the next-generation immunotherapies market are concentrating on developing innovative treatments, such as CAR T-cell therapy, to address cancers, autoimmune diseases, and infectious diseases. CAR T-cell therapy functions by genetically engineering a patient’s T cells, a type of immune cell, to express chimeric antigen receptors (CARs). For example, in January 2025, Immuneel Therapeutics Private Limited, an India-based cell and gene therapy startup, introduced Qartemi, India’s first CAR T-cell therapy. This particular therapy targets adult B-cell non-Hodgkin lymphoma by genetically modifying a patient’s immune cells to specifically identify and eradicate cancer cells, thereby presenting a highly effective and personalized treatment choice. It extends renewed optimism to patients for whom traditional treatments have failed, possessing the advantage of being more economically viable than comparable global alternatives.

Who Are The Primary Competitors In The Global Next Generation Immunotherapies Market?

Major companies operating in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/next-generation-immunotherapies-global-market-report

Which Regions Are Poised For Strategic Growth In The Next Generation Immunotherapies Market?

North America was the largest region in the next-generation immunotherapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Next Generation Immunotherapies Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21231&type=smp

Browse Through More Reports Similar to the Global Next Generation Immunotherapies Market 2026, By The Business Research Company

Natural Immune Booster Market Report 2026

https://www.thebusinessresearchcompany.com/report/natural-immune-booster-global-market-report

Cellulars Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795